Mouse Monoclonal MAVS antibody. Suitable for WB and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Recombinant Fragment Protein within Human MAVS aa 50-300.
Preservative: 0.05% Sodium azide
Constituents: PBS, 0.05% BSA
WB | |
---|---|
Human | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 2.00000-4.00000 µg/mL | Notes - |
Select an associated product type
Adapter required for innate immune defense against viruses (PubMed:16125763, PubMed:16127453, PubMed:16153868, PubMed:16177806, PubMed:19631370, PubMed:20127681, PubMed:20451243, PubMed:21170385, PubMed:23087404, PubMed:27992402, PubMed:33139700, PubMed:37582970). Acts downstream of DHX33, RIGI and IFIH1/MDA5, which detect intracellular dsRNA produced during viral replication, to coordinate pathways leading to the activation of NF-kappa-B, IRF3 and IRF7, and to the subsequent induction of antiviral cytokines such as IFNB and RANTES (CCL5) (PubMed:16125763, PubMed:16127453, PubMed:16153868, PubMed:16177806, PubMed:19631370, PubMed:20127681, PubMed:20451243, PubMed:20628368, PubMed:21170385, PubMed:23087404, PubMed:25636800, PubMed:27736772, PubMed:33110251). Peroxisomal and mitochondrial MAVS act sequentially to create an antiviral cellular state (PubMed:20451243). Upon viral infection, peroxisomal MAVS induces the rapid interferon-independent expression of defense factors that provide short-term protection, whereas mitochondrial MAVS activates an interferon-dependent signaling pathway with delayed kinetics, which amplifies and stabilizes the antiviral response (PubMed:20451243). May activate the same pathways following detection of extracellular dsRNA by TLR3 (PubMed:16153868). May protect cells from apoptosis (PubMed:16125763). Involved in NLRP3 inflammasome activation by mediating NLRP3 recruitment to mitochondria (PubMed:23582325).
IPS1, KIAA1271, VISA, MAVS, Mitochondrial antiviral-signaling protein, CARD adapter inducing interferon beta, Interferon beta promoter stimulator protein 1, Putative NF-kappa-B-activating protein 031N, Virus-induced-signaling adapter, Cardif, IPS-1
Mouse Monoclonal MAVS antibody. Suitable for WB and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Recombinant Fragment Protein within Human MAVS aa 50-300.
Preservative: 0.05% Sodium azide
Constituents: PBS, 0.05% BSA
Abcam is leading the way to address reproducibility in scientific research with our highly validated recombinant monoclonal and recombinant multiclonal antibodies. Search & select one of Abcam's thousands of recombinant alternatives to eliminate batch-variability and unnecessary animal use.
If you do not find a host species to meet your needs, our catalogue and custom Chimeric range provides scientists the specificity of Abcam's RabMAbs in the species backbone of your choice. Remember to also review our range of edited cell lines, proteins and biochemicals relevant to your target that may help you further your research goals.
Abcam antibodies are extensively validated in a wide range of species and applications, so please check the reagent specifications meet your scientific needs before purchasing. If you have any questions or bespoke requirements, simply visit the Contact Us page to send us an inquiry or contact our Support Team ahead of purchase.
MAVS also known as mitochondrial antiviral-signaling protein is a critical adaptor protein involved in the innate immune response to viral infections. This protein with a molecular weight of approximately 56 kDa is expressed on the mitochondrial membrane. It plays a major role in antiviral defense by transmitting signals from cytosolic pattern recognition receptors like RIG-I-like receptors to initiate downstream immune responses. MAVS can also be referred to as IPS-1 VISA or CARDIF in scientific literature.
The MAVS protein activates important signaling cascades to produce type I interferons and other cytokines which are essential in the antiviral response. MAVS forms a complex with other proteins on the mitochondrial membrane helping to coordinate a rapid immune reaction to viral pathogens. It acts by amplifying the signal from RIG-I and MDA5 facilitating their role in the recognition of viral RNA. By recruiting downstream signaling molecules MAVS enables the activation of transcription factors like IRF3 and NF-kB.
MAVS plays a central role in the signaling pathways that regulate innate immunity including the RIG-I-like receptor signaling pathway and the NF-kB pathway. It interacts with various proteins such as TRIF and STING in the pathways to modulate immune responses. These pathways help trigger the production of antiviral substances and maintain homeostasis within the body's defense mechanisms. MAVS provides a platform for the assembly of signaling complexes which are necessary for the propagation and amplification of the immune response signal.
MAVS is associated with conditions such as viral infections and autoimmune diseases. Dysregulation of MAVS activity has been linked to systemic lupus erythematosus where abnormal immune signaling may occur. MAVS also has connections with other proteins such as TRAF3 and TRAF6 which contribute to disease pathogenesis. Understanding the role of MAVS in these conditions may provide insights into therapeutic targets for improving disease outcomes.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
False colour image of Western blot: Anti-MAVS antibody [ABM28C8] staining at 2 ug/ml, shown in green; Rabbit Anti-GAPDH antibody [EPR16891] (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab220170 was shown to bind specifically to MAVS. A band was observed at 70 kDa in wild-type A549 cell lysates with no signal observed at this size in Mavs knockout cell line Human MAVS knockout A549 cell line ab282354 (knockout cell lysate Human MAVS knockout A549 cell lysate ab283026). To generate this image, wild-type and Mavs knockout A549 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 5% milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4°C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed ab216777) at 1/20000 dilution.
All lanes: Western blot - Anti-MAVS antibody [ABM28C8] (ab220170) at 2 µg/mL
Lane 1: Wild-type A549 cell lysate at 20 µg
Lane 2: Mavs knockout A549 cell lysate at 20 µg
Lane 2: Western blot - Human MAVS knockout A549 cell line (Human MAVS knockout A549 cell line ab282354)
Lane 2: Western blot - Human MAVS knockout A549 cell lysate (Human MAVS knockout A549 cell lysate ab283026)
Performed under reducing conditions.
Predicted band size: 57 kDa
Observed band size: 70 kDa
All lanes: Western blot - Anti-MAVS antibody [ABM28C8] (ab220170) at 2 µg/mL
Lane 1: Panc-28 cell lysate
Lane 2: HCT116 cell lysate
Predicted band size: 57 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com